61 NORTH BEACON STREET, BOSTON, MA
X4 Pharmaceuticals Enters Underwriting Agreement for 45.86M Shares
Announces Restructuring of Business Operations Designed to Drive Long-Term Value Creation
Changes in Board, Management or Compensation
Announces Closing of Upsized $85 Million Private Placement
Announces $60 Million Equity Financing with Concurrent Changes in Management and Board Leadership
News, Legal Opinion, Material Contracts
Shareholder votes
Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Q2
Q1
FY 2024
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Notice of Exempt Offering of Securities
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership